GRAY - Graybug says current cash to deliver three clinical readouts in 2023

Graybug Vision (NASDAQ:GRAY) said it plans to use its current cash to advance its eye treatments, GB-102, GB-401 and GB-501, to clinical readouts in 2023. Shares of the company rose +3.1% in premarket trading. The company's GB-102 is in development to treat wet age-related macular degeneration (wet AMD), while GB-401 is being developed to treat primary open-angle glaucoma, and GB-501 to treat inherited retinal diseases. GRAY plans to move GB-102 into a Phase 2 clinical trial in wet AMD in Q4, and expects Phase 1 trial in glaucoma treatment to start in first quarter of 2023, with safety and efficacy data expected to be available in the second quarter of 2023. The drug developer said IND submission for GB-501 is expected in the second quarter of 2023, and the data readout is expected in the fourth quarter of 2023. The company has two other drugs - GB-601 for Inherited Retinal Diseases and GB-701 for Geographic

For further details see:

Graybug says current cash to deliver three clinical readouts in 2023